Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026
Journey Medical (Nasdaq: DERM) will release its year-end 2025 financial results after market close on March 25, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Journey Medical (Nasdaq: DERM) will release its year-end 2025 financial results after market close on March 25, 2026.
The company will host a conference call and live audio webcast the same day at 4:30 p.m. ET; registration is available online and the replay will remain available about 30 days.
Details
News Market Reaction – DERM
On Mar 18, the day this news came out, DERM closed 5.07% below the previous close.
Data tracked by StockTitan Argus for the Mar 18 session.
Key Figures
- Q3 2025 total revenue
- $17.631M
- Quarter ended September 30, 2025
- Emrosi revenue
- $4.883M
- Q3 2025, U.S. launch contribution
- Gross margin
- 67.4%
- Q3 2025 gross margin
- Net loss
- $2.315M
- Q3 2025 net loss (basic and diluted $0.09/share)
- Cash and cash equivalents
- $24.948M
- Balance as of September 30, 2025
- Shelf registration size
- $150,000,000
- Form S-3 shelf filed January 15, 2026
- ATM share capacity
- 3,750,000 shares
- At-the-market equity program under shelf
- Term loan principal
- $25.0M
- SWK Credit Facility principal outstanding
Historical Context
-
Phase 1 Emrosi data showed no significant microbiome changes or safety issues.
-
Q3 2025 revenue grew 21% with improved margins and narrower net loss.
-
Announcement of timing and access details for Q3 2025 results call.
-
Pooled Phase 3 Emrosi data showed higher IGA success and lesion reduction.
-
Planned participation in October 2025 investor conferences and meetings.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
u.s. food and drug administration regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company to host conference call to discuss financial results and provide a corporate update on March 25, 2026 at 4:30 p.m. ET
SCOTTSDALE, Ariz., March 18, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its year end 2025 financial results after the U.S. financial markets close on Wednesday, March 25, 2026. Journey Medical management will conduct a conference call and audio webcast on Wednesday, March 25, 2026 at 4:30 p.m. ET.
To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to join the Journey Medical conference call. Participants can register for the conference by navigating to https://dpregister.com/sreg/10206557/103495af641. Please note that registered participants will receive their dial-in number upon registration.
A live audio webcast can be accessed on the News and Events page of the Investors section of Journey Medical’s website, www.journeymedicalcorp.com, and will remain available for replay for approximately 30 days after the conference call.
About Journey Medical Corporation
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets eight branded FDA-approved prescription drugs that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit www.journeymedicalcorp.com.
Company Contact:
Jaclyn Jaffe
Journey Medical Corporation
(781) 652-4500
ir@jmcderm.com
Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.